In the United States, approximately 30 million people suffer from disability due to osteoarthritis. In Italy, approximately 7 million people suffer from conditions that hinder common activities related to aging joints. One in five people have joint disease, the main cause of which is a degeneration of cartilage tissue, or osteoarthritis. The social cost is enormous and constantly increasing, and it represents a problem for our economy.
Life expectancy has increased significantly over the last century, and the number of people who participate in sports and lead active lives even in old age has grown, as has the number of patients with degenerative lesions of the knee, hip, and ankle.
Orthopaedists and basic scientists around the world are concerned that too many physically active, relatively young patients are being treated with knee and hip replacements for cartilage degeneration.
Platelet-Rich Plasma (PRP) has been defined by the Medical Subject Heading Database (MeSH) as a product consisting of platelets concentrated in a limited volume of plasma that can be used in various tissue regeneration procedures where growth factors act as stimulants for the healing of wounds or lesions in various tissues. Intra-articular injections of PRP into the knee have been used for many years with encouraging preliminary results: some studies have demonstrated good short-term results with PRP, superior to those obtained with hyaluronic acid.
Our study on the effects of PRP on early osteoarthritis, published a few years ago in the American journal Sports Health and awarded in Baltimore in 2012 by the AOSSM as best international publication, demonstrated that it is possible to delay joint degenerative processes and improve the quality of life in patients suffering from early osteoarthritis of the knee.
Ultimately, we want to delay joint replacement.
“The big difference between treating with cells and traditional treatments is that cells focus on regeneration,” Ramon Cugat, doctor of the Spanish national football team and one of the pioneers of this biological therapy, always told me.
We collabaorated with him for years in search of the best kind of PRP because: “not all PRP are the same”.
Today, almost 20 years later, I would say that the next step will be a new generation of PRP: “patient customized preparation,” meaning the PRP used for tendinitis will not be the same as that used for a cartilage problem, just as the preparation will be different for a patient with a baseline platelet count of 400,000 and one with 200,000.
Furthermore, the combination of PRP with various pharmacological substances, such as hyaluronic acid, will be increasingly used.
Speaking of surgeries, we can say that the idea of a “biological solution to biological problems” has encouraged the development of less invasive procedures that promote rapid and effective functional recovery. Numerous studies in the literature have demonstrated that BIO-ORTHOPAEDIC techniques can effectively treat osteocartilaginous lesions, delaying the progression of osteoarthritis.
Treatment of a cartilage injury varies depending on its size and location.
Condylar lesions smaller than 1-1.5 cm in diameter can be treated with microfractures but it must be considered that they do not allow the reformation of normal hyaline tissue and that patellar and trochlear lesions should not be treated with these methods.
A few years ago, we published a study in KSSTA on athletes treated with microfractures and followed for 15 years, highlighting the progressive degeneration, especially in large lesions.
For large lesions, autologous chondrocyte implantation (ACI), developed by Lars Peterson 30 years ago, is considered an effective procedure, capable of restoring functionally viable hyaline tissue over the long term. However the technique requires two surgeries, large incisions, high local morbidity, irregular distribution of chondrocytes, and potential graft hypertrophy. It is also expensive and not free from potential complications. To address these complications, bioengineered tissue membranes (scaffolds) have been developed to seed chondrocytes, making the surgical procedure easier and sometimes feasible under arthroscopic guidance for lesions smaller than a certain size.
These so-called “second-generation” techniques still involved two surgical steps: biopsy with subsequent in vitro cell culture and subsequent implantation. For several years, we used Hyalograft, a 3D hyaluronic acid-based membrane on which chondrocytes were seeded and cultured. The short- and medium-term results were encouraging, but the total cost of the surgery, the membrane, and the in vitro culture, during a time of economic recession, represented the main limitation to the widespread use of these techniques.
For about 15 years, we have been focusing more on performing a single surgical procedure, a “one-step surgery,” using bone marrow aspirate concentrate (BMAC) collected from the patient during surgery and using a similar membrane we used for the second-generation technique (Hyalofast). Nixon and Fortier demonstrated early chondrogenic activity in cartilage defects in horses, concluding that arthroscopic application of MSCs in equines improves the cartilage healing process. I therefore performed the first surgeries with this method on horses, and I must say I was pleased, as one of the horses I operated on came in second in the world reining championship in the USA. Given the results obtained, we began the “biological arthroplasty” project, an attempt to use a conservative biological approach to treat young patients who due to serious injuries have significant osteochondral damage to the knee — patients who would otherwise have joint replacement surgery. Our goal is to preserve the joint, reduce pain, and delay the need for joint replacement, which will require a subsequent revision given the patient’s life expectancy.
To perform a one-step cartilage transplant, 60 cc of bone marrow aspirate from the iliac crest is used, which is concentrated and activated into BMAC which is a sticky and highly malleable clot. This clot contains mesenchymal stem cells (MSCs) and growth factors (GFs). MSCs are characterized by high proliferation and the potential for multilineage differentiation into hematopoietic, adipogenic, osteogenic, and chondrogenic stem cells.
The results obtained even in large lesions (over 10 cm2) are extremely interesting and the method also works on older people (45-65 years).
We have published the results of this technique with a 14-year follow-up in the American Journal of Sports Medicine and are confident that we can broaden our indications thanks also to the use of larger membranes.
Unfortunately, in Italy, many of these techniques are still considered experimental and are not covered by the National Health Service (NHS), reducing the number of patients who could benefit from these treatments.


